The global Drugs for Asthma and COPD market was valued at US$ 43100 million in 2023 and is projected to reach US$ 65200 million by 2030, at a CAGR of 6.1% during the forecast period.
This research report provides a comprehensive analysis of the Drugs for Asthma and COPD market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Drugs for Asthma and COPD market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Drugs for Asthma and COPD, challenges faced by the industry, and potential opportunities for market players.
The global Drugs for Asthma and COPD market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Drugs for Asthma and COPD market presents opportunities for various stakeholders, including Asthma, COPD. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Drugs for Asthma and COPD market. Additionally, the growing consumer demand present avenues for market expansion.
The market for drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) is expected to witness substantial growth in the coming years. The increasing prevalence of these respiratory disorders, growing awareness about their diagnosis and management, and advancements in drug therapies are key drivers of market expansion. Bronchodilators and corticosteroids are commonly prescribed medications for asthma and COPD, and the market for these drugs is highly competitive, with several pharmaceutical companies involved in their production and distribution. However, challenges such as high treatment costs, side effects, and the availability of generic alternatives may hinder market growth. Nonetheless, the drugs for asthma and COPD market holds significant opportunities for growth, driven by the rising global burden of these respiratory conditions and the continuous development of novel therapeutic options.
Key Features:
The research report on the Drugs for Asthma and COPD market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Drugs for Asthma and COPD market.
Market Overview: The report provides a comprehensive overview of the Drugs for Asthma and COPD market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Inhalable & Nasal Spray, Oral), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Drugs for Asthma and COPD market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Drugs for Asthma and COPD market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Drugs for Asthma and COPD market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Drugs for Asthma and COPD market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Drugs for Asthma and COPD market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Drugs for Asthma and COPD market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Drugs for Asthma and COPD, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Drugs for Asthma and COPD market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Drugs for Asthma and COPD market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Inhalable & Nasal Spray
- Oral
- Others
Market segment by Application
Global Drugs for Asthma and COPD Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- GSK
- AstraZeneca
- Boehringer Ingelheim
- Vertex
- Roche
- Novartis
- Teva
- Chiesi
- Mylan
- Sumitomo Dainippon
- Merck
- Beximco
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Asthma and COPD, market overview.
Chapter 2: Global Drugs for Asthma and COPD market size in revenue.
Chapter 3: Detailed analysis of Drugs for Asthma and COPD company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Asthma and COPD Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Asthma and COPD Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Asthma and COPD Overall Market Size
2.1 Global Drugs for Asthma and COPD Market Size: 2023 VS 2030
2.2 Global Drugs for Asthma and COPD Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Asthma and COPD Players in Global Market
3.2 Top Global Drugs for Asthma and COPD Companies Ranked by Revenue
3.3 Global Drugs for Asthma and COPD Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Asthma and COPD Companies in Global Market, by Revenue in 2023
3.5 Global Companies Drugs for Asthma and COPD Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Asthma and COPD Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Asthma and COPD Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Asthma and COPD Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Asthma and COPD Market Size Markets, 2023 & 2030
4.1.2 Inhalable & Nasal Spray
4.1.3 Oral
4.1.4 Others
4.2 By Type - Global Drugs for Asthma and COPD Revenue & Forecasts
4.2.1 By Type - Global Drugs for Asthma and COPD Revenue, 2019-2024
4.2.2 By Type - Global Drugs for Asthma and COPD Revenue, 2025-2030
4.2.3 By Type - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Asthma and COPD Market Size, 2023 & 2030
5.1.2 Asthma
5.1.3 COPD
5.2 By Application - Global Drugs for Asthma and COPD Revenue & Forecasts
5.2.1 By Application - Global Drugs for Asthma and COPD Revenue, 2019-2024
5.2.2 By Application - Global Drugs for Asthma and COPD Revenue, 2025-2030
5.2.3 By Application - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Drugs for Asthma and COPD Market Size, 2023 & 2030
6.2 By Region - Global Drugs for Asthma and COPD Revenue & Forecasts
6.2.1 By Region - Global Drugs for Asthma and COPD Revenue, 2019-2024
6.2.2 By Region - Global Drugs for Asthma and COPD Revenue, 2025-2030
6.2.3 By Region - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Drugs for Asthma and COPD Revenue, 2019-2030
6.3.2 US Drugs for Asthma and COPD Market Size, 2019-2030
6.3.3 Canada Drugs for Asthma and COPD Market Size, 2019-2030
6.3.4 Mexico Drugs for Asthma and COPD Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Drugs for Asthma and COPD Revenue, 2019-2030
6.4.2 Germany Drugs for Asthma and COPD Market Size, 2019-2030
6.4.3 France Drugs for Asthma and COPD Market Size, 2019-2030
6.4.4 U.K. Drugs for Asthma and COPD Market Size, 2019-2030
6.4.5 Italy Drugs for Asthma and COPD Market Size, 2019-2030
6.4.6 Russia Drugs for Asthma and COPD Market Size, 2019-2030
6.4.7 Nordic Countries Drugs for Asthma and COPD Market Size, 2019-2030
6.4.8 Benelux Drugs for Asthma and COPD Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Drugs for Asthma and COPD Revenue, 2019-2030
6.5.2 China Drugs for Asthma and COPD Market Size, 2019-2030
6.5.3 Japan Drugs for Asthma and COPD Market Size, 2019-2030
6.5.4 South Korea Drugs for Asthma and COPD Market Size, 2019-2030
6.5.5 Southeast Asia Drugs for Asthma and COPD Market Size, 2019-2030
6.5.6 India Drugs for Asthma and COPD Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Drugs for Asthma and COPD Revenue, 2019-2030
6.6.2 Brazil Drugs for Asthma and COPD Market Size, 2019-2030
6.6.3 Argentina Drugs for Asthma and COPD Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Asthma and COPD Revenue, 2019-2030
6.7.2 Turkey Drugs for Asthma and COPD Market Size, 2019-2030
6.7.3 Israel Drugs for Asthma and COPD Market Size, 2019-2030
6.7.4 Saudi Arabia Drugs for Asthma and COPD Market Size, 2019-2030
6.7.5 UAE Drugs for Asthma and COPD Market Size, 2019-2030
7 Drugs for Asthma and COPD Companies Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Drugs for Asthma and COPD Major Product Offerings
7.1.4 GSK Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.1.5 GSK Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Drugs for Asthma and COPD Major Product Offerings
7.2.4 AstraZeneca Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim Company Summary
7.3.2 Boehringer Ingelheim Business Overview
7.3.3 Boehringer Ingelheim Drugs for Asthma and COPD Major Product Offerings
7.3.4 Boehringer Ingelheim Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.3.5 Boehringer Ingelheim Key News & Latest Developments
7.4 Vertex
7.4.1 Vertex Company Summary
7.4.2 Vertex Business Overview
7.4.3 Vertex Drugs for Asthma and COPD Major Product Offerings
7.4.4 Vertex Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.4.5 Vertex Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Drugs for Asthma and COPD Major Product Offerings
7.5.4 Roche Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.5.5 Roche Key News & Latest Developments
7.6 Novartis
7.6.1 Novartis Company Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Drugs for Asthma and COPD Major Product Offerings
7.6.4 Novartis Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.6.5 Novartis Key News & Latest Developments
7.7 Teva
7.7.1 Teva Company Summary
7.7.2 Teva Business Overview
7.7.3 Teva Drugs for Asthma and COPD Major Product Offerings
7.7.4 Teva Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.7.5 Teva Key News & Latest Developments
7.8 Chiesi
7.8.1 Chiesi Company Summary
7.8.2 Chiesi Business Overview
7.8.3 Chiesi Drugs for Asthma and COPD Major Product Offerings
7.8.4 Chiesi Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.8.5 Chiesi Key News & Latest Developments
7.9 Mylan
7.9.1 Mylan Company Summary
7.9.2 Mylan Business Overview
7.9.3 Mylan Drugs for Asthma and COPD Major Product Offerings
7.9.4 Mylan Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.9.5 Mylan Key News & Latest Developments
7.10 Sumitomo Dainippon
7.10.1 Sumitomo Dainippon Company Summary
7.10.2 Sumitomo Dainippon Business Overview
7.10.3 Sumitomo Dainippon Drugs for Asthma and COPD Major Product Offerings
7.10.4 Sumitomo Dainippon Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.10.5 Sumitomo Dainippon Key News & Latest Developments
7.11 Merck
7.11.1 Merck Company Summary
7.11.2 Merck Business Overview
7.11.3 Merck Drugs for Asthma and COPD Major Product Offerings
7.11.4 Merck Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.11.5 Merck Key News & Latest Developments
7.12 Beximco
7.12.1 Beximco Company Summary
7.12.2 Beximco Business Overview
7.12.3 Beximco Drugs for Asthma and COPD Major Product Offerings
7.12.4 Beximco Drugs for Asthma and COPD Revenue in Global Market (2019-2024)
7.12.5 Beximco Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Drugs for Asthma and COPD Market Opportunities & Trends in Global Market
Table 2. Drugs for Asthma and COPD Market Drivers in Global Market
Table 3. Drugs for Asthma and COPD Market Restraints in Global Market
Table 4. Key Players of Drugs for Asthma and COPD in Global Market
Table 5. Top Drugs for Asthma and COPD Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Drugs for Asthma and COPD Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Drugs for Asthma and COPD Revenue Share by Companies, 2019-2024
Table 8. Global Companies Drugs for Asthma and COPD Product Type
Table 9. List of Global Tier 1 Drugs for Asthma and COPD Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Asthma and COPD Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Drugs for Asthma and COPD Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Drugs for Asthma and COPD Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Drugs for Asthma and COPD Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Drugs for Asthma and COPD Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Drugs for Asthma and COPD Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Drugs for Asthma and COPD Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Drugs for Asthma and COPD Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Drugs for Asthma and COPD Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Drugs for Asthma and COPD Revenue, (US$, Mn), 2025-2030
Table 30. GSK Company Summary
Table 31. GSK Drugs for Asthma and COPD Product Offerings
Table 32. GSK Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 33. GSK Key News & Latest Developments
Table 34. AstraZeneca Company Summary
Table 35. AstraZeneca Drugs for Asthma and COPD Product Offerings
Table 36. AstraZeneca Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 37. AstraZeneca Key News & Latest Developments
Table 38. Boehringer Ingelheim Company Summary
Table 39. Boehringer Ingelheim Drugs for Asthma and COPD Product Offerings
Table 40. Boehringer Ingelheim Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 41. Boehringer Ingelheim Key News & Latest Developments
Table 42. Vertex Company Summary
Table 43. Vertex Drugs for Asthma and COPD Product Offerings
Table 44. Vertex Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 45. Vertex Key News & Latest Developments
Table 46. Roche Company Summary
Table 47. Roche Drugs for Asthma and COPD Product Offerings
Table 48. Roche Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 49. Roche Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Drugs for Asthma and COPD Product Offerings
Table 52. Novartis Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 53. Novartis Key News & Latest Developments
Table 54. Teva Company Summary
Table 55. Teva Drugs for Asthma and COPD Product Offerings
Table 56. Teva Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 57. Teva Key News & Latest Developments
Table 58. Chiesi Company Summary
Table 59. Chiesi Drugs for Asthma and COPD Product Offerings
Table 60. Chiesi Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 61. Chiesi Key News & Latest Developments
Table 62. Mylan Company Summary
Table 63. Mylan Drugs for Asthma and COPD Product Offerings
Table 64. Mylan Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 65. Mylan Key News & Latest Developments
Table 66. Sumitomo Dainippon Company Summary
Table 67. Sumitomo Dainippon Drugs for Asthma and COPD Product Offerings
Table 68. Sumitomo Dainippon Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 69. Sumitomo Dainippon Key News & Latest Developments
Table 70. Merck Company Summary
Table 71. Merck Drugs for Asthma and COPD Product Offerings
Table 72. Merck Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 73. Merck Key News & Latest Developments
Table 74. Beximco Company Summary
Table 75. Beximco Drugs for Asthma and COPD Product Offerings
Table 76. Beximco Drugs for Asthma and COPD Revenue (US$, Mn) & (2019-2024)
Table 77. Beximco Key News & Latest Developments
List of Figures
Figure 1. Drugs for Asthma and COPD Segment by Type in 2023
Figure 2. Drugs for Asthma and COPD Segment by Application in 2023
Figure 3. Global Drugs for Asthma and COPD Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Drugs for Asthma and COPD Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Drugs for Asthma and COPD Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Asthma and COPD Revenue in 2023
Figure 8. By Type - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 9. By Application - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 10. By Type - Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 12. By Application - Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 14. By Region - Global Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 15. By Country - North America Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 16. US Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 20. Germany Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 21. France Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 28. China Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 32. India Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 34. Brazil Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Drugs for Asthma and COPD Revenue Market Share, 2019-2030
Figure 37. Turkey Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Drugs for Asthma and COPD Revenue, (US$, Mn), 2019-2030
Figure 41. GSK Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. AstraZeneca Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Boehringer Ingelheim Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Vertex Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Roche Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Novartis Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Teva Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Chiesi Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Mylan Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Sumitomo Dainippon Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Merck Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Beximco Drugs for Asthma and COPD Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
